DNMT3A mutations are present in approximately 10%–20% hematological malignancies, with the R882 site being a unique mutation hotspot, conferring dominant-negative inhibition against the wild-type DNMT3A enzyme and poor prognosis52. The gene discussed is DNMT3A; the disease is hematologic disorder.